Updates, Insights & Perspectives

Summary The JPM Healthcare Conference 2026 marked a clear shift in sentiment across the life sciences sector. After two years of constrained capital and valuation compression, investors and strategic buyers are cautiously re-engaging, supported by improving venture deployment, stabilizing interest rates and renewed M&A activity. However, funding remains selective, with a strong emphasis on execution, regulatory readiness and capital efficiency.   Drawing on direct commentary

Executive Summary Artificial intelligence has become the most overused — and often misunderstood — term in modern biotech. Dozens of companies now claim to be “AI-driven”, yet only a small fraction have meaningfully integrated AI into the scientific and operational backbone of their organization. For many, AI is a slide deck accessory; for few, it is a strategic partner that shapes decision-making, compresses timelines, and de-risks development. As capital becomes more select

Executive Summary For more than half a century, drug development has centered on a single dominant paradigm: molecules as the primary drivers of therapeutic innovation. But the future is moving toward something fundamentally different — multi-modal therapeutic systems  that integrate drugs with localized delivery, AI-guided optimization, biomarkers, imaging, and patient-centric digital tools. These systems do not replace drug innovation; they amplify it , unlocking therapeuti

Executive Summary The global biotech sector has entered one of its most capital-constrained periods in recent history. Venture dollars have tightened, valuations have recalibrated, and public markets have become increasingly selective. Yet the underlying need for innovation — particularly in oncology, rare disease, and CNS disorders — has never been greater. In this environment, the traditional biotech model of large internal teams, expensive wet-lab infrastructure, and long,

Executive Summary For decades, oncology drug development has been measured through two dominant lenses: efficacy  and safety . While these remain essential, they no longer tell the full story of whether a therapy truly delivers value in real-world cancer care. An additional dimension — patient burden  — is now emerging as a critical determinant of therapeutic success, especially in populations such as non–small cell lung cancer (NSCLC), where most patients are elderly, medica

Executive Summary Global cancer care has become increasingly complex, expensive, and systemically burdensome. Despite remarkable innovations in molecular targets and immuno-oncology, many patients worldwide still face challenges linked not to the drug , but to the way drugs are delivered . Toxicity, accessibility, treatment interruptions, and limited applicability to older or medically fragile populations remain persistent barriers. Localized therapy — treatments that act dir

Executive Summary For years, precision medicine has been defined almost exclusively through the lens of genomic testing and targeted drugs. But as the field matures, a new reality is becoming clear: precision cannot be achieved through molecules alone . The next decade of innovation will belong to drug–device combinations — technologies that integrate therapeutic agents with delivery systems engineered to ensure the right dose reaches the right place at the right time. From n

Executive Summary For more than two decades, oncology innovation has been defined by the pursuit of new targets, new pathways, and new molecular entities. This model has delivered extraordinary breakthroughs — but it has also created diminishing returns, escalating costs, and widening gaps between scientific promise and real-world patient benefit. The next wave of oncology progress is unlikely to come from discovering ever more complex molecules. Instead, it will come from re